RTT Premium Stocks

Home
United States
Washington D.C., DC
RTT Premium Stocks

RTT Biotech Investor and RTT Intelligent Investor services give subscribers the edge to make more successful investments. Welcome to RTTNews Premium stocks.

For over 20 years, RTTNews has been providing news and analysis from around the globe that can impact individual stocks and broader markets to leading banks, brokerages and hedge funds. Now RTT is offering the same information to individual investors and traders. RTT Premium Stocks consists of RTT Biotech Investor and RTT Intelligent Investor

RTT Biotech Investor - Biotech investment is one of th

e exciting spaces in the stock market. The companies in this sector focus on clinical research and development of new drugs. There is tremendous potential for stocks to deliver outstanding gains when companies report positive trial data or when their drugs obtain FDA approval. At RTTNews, a dedicated team tracks these companies and developments. As a subscriber, you will have access to all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions. RTT Intelligent Investor - is your all-encompassing guide to profitable investment decisions. The daily newsletter filters through though mounds of data to provide timely and valuable information to subscribers. Our premium alerts identify stocks with upside potential, handpicked after meticulous research and analysis to help you benefit from the stock market in the next few days/weeks/months. Our premium services give subscribers the edge they need to make more successful investments and trades by discovering opportunities long before they catch the attention of mainstream investors. Our stocks have consistently and significantly outperformed the broader markets. Unlike other services that highlight a few top gainers, we provide a complete performance table for all the stocks we publish, so you can see the true performance of the service at any given time. By incorporating our research into your trading strategy, you can find the best trading opportunities every day. Let our experts provide you with timely insight and analysis, so you can focus on your investment strategies. Along with our in-depth research and concise reports, we also provide technical analysis that identify key support/resistance levels, stock trends, chart patterns and other key indicators when applicable. Sign up today for your RISK-FREE 7 day trial, and let us help you find the best investment and trading opportunities.

04/27/2026

𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝘀𝘁𝗼𝗰𝗸𝘀 𝗱𝗼𝗻’𝘁 𝘄𝗮𝗶𝘁.
They move on catalysts—FDA decisions, clinical results, and breakthrough data.

Today’s Watchlist:

𝗢𝗥𝗞𝗔 𝗟𝗲𝗮𝘃𝗲𝘀 𝗮 𝗟𝗮𝘀𝘁𝗶𝗻𝗴 𝗜𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗼𝗻 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀

Oruka Therapeutics, Inc. (ORKA) has reported compelling Week 16 data from its ongoing Phase 2a EVERLAST-A trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met the primary endpoint, with 40 of 63 patients (63.5%) treated with ORKA-001 achieving complete skin clearance (PASI 100) at Week 16.

The stock was trading around $16.56 when we alerted readers on September 18, 2025. In premarket trading today, it surged to as high as $100.

𝗦𝘁𝗮𝗿𝘁 𝘆𝗼𝘂𝗿 𝗳𝗿𝗲𝗲 𝟳-𝗱𝗮𝘆 𝘁𝗿𝗶𝗮𝗹 𝗻𝗼𝘄. 𝗦𝘁𝗮𝘆 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗮𝗿𝗸𝗲𝘁.
https://shorturl.at/HIUMW

04/22/2026

𝗔 𝗧𝗮𝗹𝗲 𝗼𝗳 𝗧𝘄𝗶𝘀𝘁 - 𝗚𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗣𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗢𝗻 𝗧𝗿𝗮𝗰𝗸

Twist Bioscience Corp. (TWST), a synthetic biology company, continues to gain momentum as it advances toward profitability, supported by steady revenue growth, while its stock has been gaining traction over recent months.

The company is scheduled to report fiscal Q2 2026 results (ended March 31, 2026) on May 4, 2026, before market open. For the quarter, revenue is expected to be approximately $107–$108 million, representing about 16% year-over-year growth at the midpoint.

When we alerted readers to TWST on November 10, 2025, it was trading around $31. The stock touched a 52-week high of $65.10 yesterday, reflecting a gain of over 100% in less than 6 months.

You can read the full report here:

https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3592003&type=bipm

04/21/2026

𝗪𝗶𝗹𝗹 𝗞𝘆𝘃𝗲𝗿𝗻𝗮 𝗺𝗮𝗸𝗲 𝗵𝗶𝘀𝘁𝗼𝗿𝘆?

Kyverna Therapeutics, Inc. (KYTX) is set to host a conference call on Wednesday, April 22, 2026, at 7:00 a.m. ET to discuss key pipeline updates.

The company will present primary analysis from its KYSA-8 Phase 2 registrational trial of Miv-cel in stiff person syndrome, along with longer-term follow-up data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis (gMG).

Miv-cel is a fully human, autologous CD19-targeting CAR-T cell therapy with CD28 co-stimulation. While CAR-T therapies have revolutionized cancer treatment, none are approved for autoimmune diseases yet.

If ongoing clinical results continue to translate into regulatory success, Miv-cel could become the first approved therapy for stiff person syndrome (SPS) and a landmark CAR T-cell therapy in autoimmune disease.

When KYTX was profiled on our site on September 30, 2025, it was trading at $5.86. The stock subsequently rallied over the following months, reaching a 52-week high of $13.67 on December 15, 2025, before partially giving back gains. The stock closed yesterday’s trading at $11.25, up 13.29%.

You can read the full report here.

https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3640627&type=bipm

04/20/2026

𝗡𝗞𝗧𝗥 𝗖𝗿𝗼𝘀𝘀𝗲𝘀 𝗧𝗵𝗲 𝗠𝗮𝗴𝗶𝗰𝗮𝗹 $𝟭𝟬𝟬 𝗠𝗮𝗿𝗸

Nektar Therapeutics (NKTR) hit a milestone today, with shares touching a 52-week high of $103.25 in early trading.

The catalyst: the company reported new data from a blinded 16-week extension of its Phase 2b REZOLVE-AA study, showing that responses continued to deepen over time in patients with severe-to-very-severe alopecia areata treated with Rezpegaldesleukin.

NKTR was featured on our site on June 11, 2025, when it was trading at $11.25, and again on April 7, 2026, when it was at $74.26. Did you buy the stock?

You can read the full report here:

https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3637255&type=lr

04/13/2026

𝗔𝗟𝗟𝗢 𝗦𝗵𝗶𝗻𝗲𝘀 𝗕𝗿𝗶𝗴𝗵𝘁 𝗼𝗻 𝗦𝘁𝗿𝗼𝗻𝗴 𝗖𝗲𝗺𝗮-𝗖𝗲𝗹 𝗦𝗶𝗴𝗻𝗮𝗹𝘀

Allogene Therapeutics Inc. (ALLO) touched a new 52-week high of $4.46 in early trading today, powered by encouraging Phase 2 data for its investigational therapy cema-cel in large B-cell lymphoma (LBCL).

Early results suggest Cema-cel may help clear or significantly reduce minimal residual disease (MRD) - the tiny, often undetectable traces of cancer cells that can linger after treatment - and may also help delay disease relapse.

(MRD refers to a very small number of cancer cells that remain in the body after treatment and can only be detected with highly sensitive tests. Source: National Cancer Institute.)

We profiled ALLO on our site on January 9, 2026, when it was trading at $1.66. Today's 52-week high reflects a gain of over 160% in a little over 3 months.

You can read the full report here:

https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3609030&type=bipm

04/10/2026

𝗗𝗶𝗱 𝗥𝗟𝗠𝗗 𝗰𝗼𝗺𝗲 𝘁𝗼 𝘁𝗵𝗲 𝗥𝗘𝗦𝗖𝗨𝗘 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼?

Shares of Relmada Therapeutics Inc. (RLMD) have been climbing steadily as its lead candidate, NDV-01, advances in non-muscle invasive bladder cancer. The stock touched a new 52-week high of $7.94 in early trading today.

In a Phase 2 trial reported this March, NDV-01 delivered strong response rates, with benefits lasting up to 12 months, and was generally well tolerated in patients with high-risk disease.

The drug is now expected to move into a Phase 3 study called RESCUE by mid-2026, targeting both patients who did not respond to prior BCG therapy and those in the intermediate-risk adjuvant setting.

When we highlighted RLMD on December 16, 2025, the stock was trading at $4.66. Today’s 52-week high of $7.94 reflects a gain of about 70% in just four months.

You can read the full report here: https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3604390&type=bimb

04/02/2026

𝗘𝗿𝗮𝘀𝗰𝗮: 𝗘𝗿𝗮𝘀𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿, 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗚𝗮𝗶𝗻𝘀

Shares of Erasca Inc. (ERAS), which have been on a steady climb since November 2025, touched a 52-week high of $18.14 today. This clinical-stage precision oncology company, with a bold mission to "erase cancer", has a couple of trial catalysts to watch in the coming months.

When we alerted readers to ERAS on November 18, 2025, it was trading at $2.87. Today’s 52-week high reflects a gain of over 530% in less than 5 months.

Read the full report here:

https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3596197&type=bipm

03/31/2026

𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗠&𝗔 𝗶𝘀 𝗼𝗻 𝗳𝗶𝗿𝗲!

Two blockbuster deals have been announced today.

Centessa Pharma (CNTA) is acquired by Lilly for $6.3 billion or $47 per share

Apellis Pharma (APLS) is acquired by Biogen for $5.6 billion or $41 per share

Were these stocks on your radar?

When we alerted readers to CNTA on October 29, 2025, it was trading at $25.05, making today’s acquisition price of $47 an 87% gain in just five months. Similarly, APLS was profiled on our site on April 2, 2025, at $22.53, meaning the acquisition price of $41 reflects an 82% gain in one year.

Read the full reports here:

https://www.rttnews.com/3526173/apellis-looks-to-unlock-blockbuster-potential-for-empaveli-syfovre-on-a-path-to-profitability.aspx

https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3587170&type=bipm

03/30/2026

𝗦𝗼 𝗟𝗼𝗻𝗴, 𝗞𝗲𝘇𝗮𝗿: 𝗔 𝗡𝗲𝘄 𝗖𝗵𝗮𝗽𝘁𝗲𝗿 𝗕𝗲𝗴𝗶𝗻𝘀

Shares of Kezar Life Sciences Inc. (KZR) touched a new 52-week high of $7.55 today, on news of the company getting acquired by Aurinia Pharmaceuticals Inc. (AUPH) for $6.955 in cash per share plus one non-transferable contingent value right (CVR). The transaction is expected to close in the second quarter of 2026.

When we alerted readers to KZR on October 8, 2025, it was trading at $3.89. Today’s 52-week high represents a gain of over 90% in less than 6 months.

Read more here: https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3580480&type=bipm

&A

03/27/2026

𝗗𝗶𝗱 𝗞𝗼𝗱𝗶𝗮𝗸’𝘀 𝗚𝗟𝗢𝗪(𝗶𝗻𝗴) 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗠𝗮𝗸𝗲 𝗬𝗼𝘂𝗿 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗦𝗵𝗶𝗻𝗲?

Approved intravitreal anti-VEGF therapies for diabetic retinopathy, such as Eylea, typically require 7 to 9 injections in the first year of treatment. This frequent dosing can be burdensome, highlighting the need for therapies that reduce injection frequency, improve durability in the eye, and minimize side effects while maintaining strong clinical outcomes.

One such investigational therapy is Kodiak Sciences’ (KOD) Zenkuda (tarcocimab tedromer). In its second Phase 3 study, dubbed GLOW2, results reported yesterday show that Zenkuda demonstrated superiority over sham treatment, offering the potential for effective disease control with fewer injections and representing a patient-friendly advancement in DR therapy.

We alerted readers to KOD on Sep.23, 2025, when it was at $15, and again on Mar.5, 2026, when it was at $26.51. The stock touched a 52-week high of $40.46 yesterday, which marks a gain of nearly 170% in just 6 months.

You can read the full report here:

https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3628339&type=bimb

03/26/2026

𝗠𝗶𝘀𝘀𝗲𝗱 𝗘𝗟𝗩𝗡’𝘀 𝟭𝟬𝟬% 𝗥𝘂𝗻?

After a year of solid progress advancing its lead investigational drug in chronic myeloid leukemia (CML), a rare blood cancer, Enliven Therapeutics (ELVN) now has key data readouts, regulatory milestones, and the planned ENABLE-2 pivotal study lined up for 2026. It is therefore no surprise that the stock is hitting fresh 52-week highs as investor interest builds.

When we alerted readers to ELVN on November 10, 2025, it was trading at $17.82. Yesterday’s high of $36.65 equates to a gain of more than 100% in less than 5 months.

Read the full report here:

https://www.rttnews.com/products/biotechinvestor/story.aspx?id=3593458&type=bipm

Address

Washington D.C., DC

Telephone

+12027694900

Website

https://www.rttnews.com/products/biotechinvestor.aspx

Alerts

Be the first to know and let us send you an email when RTT Premium Stocks posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Joseph LaFleur and Associates Psychotherapy a
Telehealth & 2001 L Street NW Ste 500

Want your practice to be the top-listed Clinic in Washington D.C.?